Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report

Low‐dose interferon‐α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high‐risk polycythemia vera patients.

Detalles Bibliográficos
Autores principales: Driessen, Christoph, Noppen, Christoph, Boonen, Georg, Drewe, Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493450/
https://www.ncbi.nlm.nih.gov/pubmed/34631086
http://dx.doi.org/10.1002/ccr3.4903
_version_ 1784579114933420032
author Driessen, Christoph
Noppen, Christoph
Boonen, Georg
Drewe, Juergen
author_facet Driessen, Christoph
Noppen, Christoph
Boonen, Georg
Drewe, Juergen
author_sort Driessen, Christoph
collection PubMed
description Low‐dose interferon‐α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high‐risk polycythemia vera patients.
format Online
Article
Text
id pubmed-8493450
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84934502021-10-08 Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report Driessen, Christoph Noppen, Christoph Boonen, Georg Drewe, Juergen Clin Case Rep Case Reports Low‐dose interferon‐α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high‐risk polycythemia vera patients. John Wiley and Sons Inc. 2021-10-06 /pmc/articles/PMC8493450/ /pubmed/34631086 http://dx.doi.org/10.1002/ccr3.4903 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Driessen, Christoph
Noppen, Christoph
Boonen, Georg
Drewe, Juergen
Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title_full Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title_fullStr Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title_full_unstemmed Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title_short Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
title_sort complete hematological and major molecular response through treatment with low‐dose interferon alpha 2a in high‐risk polycythemia vera patient: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493450/
https://www.ncbi.nlm.nih.gov/pubmed/34631086
http://dx.doi.org/10.1002/ccr3.4903
work_keys_str_mv AT driessenchristoph completehematologicalandmajormolecularresponsethroughtreatmentwithlowdoseinterferonalpha2ainhighriskpolycythemiaverapatientacasereport
AT noppenchristoph completehematologicalandmajormolecularresponsethroughtreatmentwithlowdoseinterferonalpha2ainhighriskpolycythemiaverapatientacasereport
AT boonengeorg completehematologicalandmajormolecularresponsethroughtreatmentwithlowdoseinterferonalpha2ainhighriskpolycythemiaverapatientacasereport
AT drewejuergen completehematologicalandmajormolecularresponsethroughtreatmentwithlowdoseinterferonalpha2ainhighriskpolycythemiaverapatientacasereport

Ejemplares similares